☆ 4.6 Meeting Abstract

Sustained Efficacy and Safety of Burosumab, an Anti-FGF23 Monoclonal Antibody, for 88 Weeks in Children and Early Adolescents with X-Linked Hypophosphatemia (XLH)

JOURNAL OF BONE AND MINERAL RESEARCH (2018)

Add to Collection

Journal

JOURNAL OF BONE AND MINERAL RESEARCH
Volume 33, Issue -, Pages 120-120

Publisher

WILEY

Keywords

-

Categories

Endocrinology & Metabolism

Funding

  1. Ultragenyx Pharmaceutical Inc.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.